genedrive PLC (AIM:GDR) said new clinical guidance on screening to prevent antibiotic hearing loss (AHL) in babies should drive demand for its breakthrough diagnostic device.
The updated advice follows work carried out by researchers working with the Manchester University NHS Foundation Trust and Liverpool Women's Hospital using the company’s assay designed specifically for use in AHL.
It focuses on the management of genetic mutations and their role in hearing loss as a result of antibiotics, known as ototoxicity.
The AHL assay, which will be distributed by Inspiration Healthcare, remains on the track for launch in the summer.
genedrive chief executive David Budd said: “Despite the emergence of COVID-19, our clinical partners showed huge dedication in keeping this important project on-track, becoming the first in the world to generate valuable information on the utility of this approach in an emergency care setting.
“As we see updated guidance and greater awareness to the requirement for genetic testing, we only expect increased interest in our novel assay."